Abstract 216P
Background
Seminomas form around 50% of germ cell tumours of testes. It commonly occurs during third decade. It is highly chemo sensitive and radio sensitive. Those patients who recur during surveillance for early stage can be salvaged by treatment with chemotherapy or radiotherapy most of the times.
Methods
Data was collected from master case sheets of seminoma patients treated over a period of five years from January 2013 to December 2017 at department of Madras medical college, Chennai.
Results
28 patients had seminoma of testes with a median age of 37 years. All patients had classical type histopathology. Right testis was more commonly involved (n=21) than left (n=7). 4 patients had seminoma arising from undescended testes. 10.7% (n=3) patients had elevated beta hcg and 28.5% (n=8) had elevated LDH. 9 patients had stage I, 12 patients had stage II and 7 patients had stage III disease. 3 patients had trans scrotal violation at peripheral hospital. 6 patients with stage I received paraaortic nodal irradiation with a mean dose of 24Gy of which 3 patients received inguinal irradiation also. All stage II and stage III patients received adjuvant chemotherapy with BEP regimen with minimum of 3 cycles. 2.5 year DFS and OS in stage I was 88.9% (n=8) and 100% (n=9) respectively. 2.5 year DFS and OS in stage II was 83.3% (n=10) and 91.6% (n=11) respectively. 2.5 year DFS and OS was 71.4% (n=5) and 71.4% (n=5) respectively.
Conclusions
Patients presented with advanced stage compared to that given in literature due to ignorance. Treatment results were comparable with that given in the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sivasubramaniam Kumaravelu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session